Treatment with CPA, an agonist of the adenoinse A1 receptor, and CGS21680, an agonist of the adenosine A2A receptor, for 2 weeks caused ventriculomegaly in 37% of the agonist-treated rats (n = 27, Figure 5D). Here, ADORA2A is linked to Ventriculomegaly.